June 25, 2021


Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post- COVID-19 Pulmonary Fibrosis




June 24, 2021


Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer




June 22, 2021


A Prospective Study in More Than 1,000 Osteoporosis Patients Concluded That Binosto® (Buffered Soluble Alendronate) May Increase Patient Satisfaction, Long-Term Adherence and Therefore Efficacy




June 13, 2021


Cortus Develops Next Generation High-End RISC-V CPU Core for HPC




May 25, 2021


Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech




April 29, 2021


EnOcean Joins Cisco DNA Spaces to bring Self-Powered IoT Devices to Smart Spaces




April 26, 2021


Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific




March 25, 2021


Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen and Strategic Equity Investment by Seagen




March 24, 2021


WISeKey $WKEY Partners with Cortus to Secure Automated Vehicles Capable of Controlling All Aspects of Driving Without Human Intervention




March 01, 2021


EnOcean Joins Cisco DNA Spaces to bring Self-Powered IoT Devices to Smart Spaces




January 26, 2021


WENZEL receives Top 100 Award for the third time




January 20, 2021


WENZEL UK Opens New Technology Centre